<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240821</url>
  </required_header>
  <id_info>
    <org_study_id>IND 133013 Extension Study</org_study_id>
    <nct_id>NCT04240821</nct_id>
  </id_info>
  <brief_title>Theophylline for Treatment of Pseudohypoparathyroidism</brief_title>
  <official_title>Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ashley Shoemaker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized
      by early-onset obesity, short stature, hormone resistance and cognitive impairment. This
      phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor,
      in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, improve
      glucose tolerance and decrease hormone resistance in children and young adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial Objectives

        1. The primary objective of this study is to evaluate the long-term safety of theophylline
           in patients with PHP.

        2. The secondary objectives of this study are to evaluate changes in BMI, hormone
           resistance and epiphyseal closure associated with theophylline treatment of patients
           with PHP.

      Study Design The proposed study is a single center, 24-month open label extension clinical
      trial for patients with PHP who complete the randomized clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label extension study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Treatment-emergent adverse events will be compared before and during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>24 months</time_frame>
    <description>Change in BMI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Pseudohypoparathyroidism</condition>
  <condition>Pseudohypoparathyroidism Type 1a</condition>
  <condition>Albright Hereditary Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>Open-label theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral theophylline - either once daily capsule or q6h elixir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline ER</intervention_name>
    <description>Oral theophylline</description>
    <arm_group_label>Open-label theophylline</arm_group_label>
    <other_name>Theophylline elixir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Successful completion of the randomized clinical trial &quot;Phase 2 Study of
             Theophylline Treatment of Pseudohypoparathyroidism IND 133103 (11/1/2016)&quot;.

        Exclusion Criteria:

          1. History of a seizure disorder unrelated to hypocalcemia

          2. History of a cardiac arrhythmia (not including bradycardia)

          3. Hepatic insufficiency including cirrhosis and acute hepatitis (AST or ALT &gt;3x upper
             limit of normal)

          4. Congestive heart failure

          5. Current cigarette use or alcohol abuse

          6. Pregnancy or intention to become pregnant during the next year

          7. Active peptic ulcer disease

          8. Current use of medications known to effect theophylline levels

          9. History of hypersensitivity to theophylline or other medication components

         10. Unable to comply with study procedures in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Shoemaker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.facebook.com/pseudohypoparathyroidism</url>
    <description>Research Group Facebook Page</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Ashley Shoemaker</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudohypoparathyroidism</mesh_term>
    <mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After publication</ipd_time_frame>
    <ipd_access_criteria>University faculty</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

